HealthDay News – Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a study published online July 20 in JAMA Oncology.

Igor Puzanov, MD, from Roswell Park Cancer Institute in Buffalo, New York, and colleagues used a post hoc subgroup analysis of pooled data to examine the association of BRAF wild-type (WT) or BRAF V600E/K-mutant status and prior BRAFi receipt with or without MEKi therapy with response to pembrolizumab among 1558 patients with advanced melanoma from 3 multisite studies.

The researchers found that in the overall study population, the objective response rate (ORR), 4-year progression-free survival (PFS) rate, and 4-year overall survival (OS) rate were 38.3, 22.0, and 36.9%, respectively. For 1124 patients with BRAF WT and 434 with BRAF V600E/K-mutant melanoma, the ORRs were 39.8 and 34.3%, respectively; 4-year PFS rates were 22.9 and 19.8%, respectively; and 4-year OS rates were 37.5 and 35.1%, respectively. Patients with BRAF V600E/K-mutant melanoma who had or had not previously received BRAFi with or without MEKi therapy had ORRs of 28.4 and 44.2%, respectively; 4-year PFS rates of 15.2 and 27.8%, respectively; and 4-year OS rates of 26.9 and 49.3%, respectively.

Related Articles

“The 1558 patients pooled from three pivotal trials form, to our knowledge, the largest data set reported for this critical analysis of the association of BRAF V600E/K mutation and prior BRAF-directed therapy with therapeutic outcomes of single-agent programmed death 1 blockade,” the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Merck, which manufactures pembrolizumab and provided funding for the study.

Abstract/Full Text (subscription or payment may be required)